FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

AbbVie Inc.

ABBVHealthcare

Generated Aug 19, 2026, 11:20 PM UTC

analytical score -7

ABBV (AbbVie Inc.) analytical snapshot. Revenue grew +8.6% YoY to $61.16B. 5-year revenue CAGR +1.7%; 10y CAGR +10.1%. Net margin at 6.91% (contracting ▼). Market cap $470.00B at $265.97 per share. Trailing P/E 112.70, P/S 7.68. EV/Operating income ≈ 35.02 (EV $527.93B). Risk: Elevated. Macro: Risk-on · Supportive. Composite analytical score -7 (data confidence 82%). Descriptive analytics from public filings — not investment advice.

Market cap
$470.00B
1.77B shares
Price
$265.97
NYQ
P/E (ttm)
112.70
Revenue (FY)
$61.16B
YoY +8.6%
Net margin
6.91%
▼ 13.48pp
Free cash flow
$17.82B
29.13% margin
Risk level
Elevated

Free SEC analysis

— computed from SEC filings, free to read
Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst
score 30Improving
80% conf

Latest annual report (10-K) filed Feb 20, 2026. Latest quarterly report (10-Q) filed Aug 3, 2026. 20 recent 8-K material-event filings in the index.

  • Latest annual report (10-K) filed Feb 20, 2026.
  • Latest quarterly report (10-Q) filed Aug 3, 2026.
  • 20 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference AbbVie Inc.; broad institutional reporting.
  • Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., K2 PRINCIPAL FUND, L.P., Saranac Partners Ltd.
  • 1 recent 13D activist/beneficial-ownership filings — potential catalyst.
  • 19 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 20, 2026
Annual report
Latest 10-Q
Aug 3, 2026
8-K (recent)
20
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
1
Recent 13F institutional filers (SEC EDGAR full-text)
FilerFormFiled
THURSTON, SPRINGER, MILLER, HERD & TITAK, INC.13F-HRMay 14, 2024
K2 PRINCIPAL FUND, L.P.13F-HRApr 30, 2015
Saranac Partners Ltd13F-HRDec 5, 2025
Pathway Financial Advisers, LLC13F-HRJul 19, 2024
Pathway Financial Advisers, LLC13F-HRJul 19, 2024
Recent 8-K material events
DateFormDescription
Aug 18, 20268-KFORM 8-K
Aug 5, 20268-KFORM 8-K
Jul 31, 20268-K8-K
Jul 6, 20268-K8-K
Jun 22, 20268-KFORM 8-K
May 12, 20268-KFORM 8-K
Apr 29, 20268-K8-K
Apr 3, 20268-K8-K
Sources:SEC EDGAR — Company FilingsSEC EDGAR — Full-Text Search
Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst
score 3Stable
68% conf

1 positive signal(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.

  • Operating cash flow exceeds net income: OCF is 4.50x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
  • 1 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
Revenue
$61.16B
+8.6% YoY
Gross profit
$12.07B
+12.7% YoY
Operating income
$15.07B
+65.0% YoY
Net income
$4.23B
-1.2% YoY
Operating cash flow
$19.03B
+1.2% YoY
Capex
$1.21B
+24.6% YoY
Total assets
$133.96B
-0.9% YoY
Long-term debt
$64.50B
-3.5% YoY
Filing quality score
72/100
1 new disclosures
SEC XBRL metric changes (latest annual vs prior)
MetricPrior yearLatest yearChange% Change
Revenue$56.33B$61.16B$4.83B+8.6%
Gross profit$10.71B$12.07B$1.36B+12.7%
Operating income$9.14B$15.07B$5.94B+65.0%
Net income$4.28B$4.23B$-52.0M-1.2%
Operating cash flow$18.81B$19.03B$224.0M+1.2%
Capex$974.0M$1.21B$240.0M+24.6%
Total assets$135.16B$133.96B$-1.20B-0.9%
Long-term debt$66.84B$64.50B$-2.34B-3.5%
Cash & equivalents$5.52B$5.23B$-295.0M-5.3%
Stockholders equity$3.33B$-3.27B$-6.59B-198.3%
Inventory$4.18B$4.95B$770.0M+18.4%
Accounts receivable$10.92B$12.59B$1.67B+15.3%
SG&A expense$14.75B$14.01B$-742.0M-5.0%
Interest expense$2.81B$2.89B$85.0M+3.0%
XBRL disclosure changes (new vs dropped concepts)
TypeConcepts
AddedPrepaidExpenseAndOtherAssetsCurrent
RemovedAccountsPayableCurrent, AccruedIncomeTaxesNoncurrent, AccruedRoyaltiesCurrent, AdvertisingExpense, BusinessAcquisitionsProFormaNetIncomeLoss, BusinessAcquisitionsProFormaRevenue, BusinessCombinationContingentConsiderationLiabilityCurrent, BusinessCombinationContingentConsiderationLiabilityNoncurrent, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit
Risk language in filing text (EDGAR full-text search)
TermSeverityRecentPriorStatus
Impairment chargemedium58Ongoing
Restructuringmedium58Ongoing
Off-balance sheet arrangementsmedium52Ongoing
Related party transactionslow20NEW
Filing signal breakdown
Red flags: 0
Positive: 1
Watch: 0
Red flags
Positive
Watch
Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports
Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst
score -5Stable
80% conf

Revenue grew +8.6% YoY to $61.16B. 5-year revenue CAGR +1.7%; 10y CAGR +10.1%. Net margin at 6.91% (contracting ▼).

  • Revenue grew +8.6% YoY to $61.16B.
  • 5-year revenue CAGR +1.7%; 10y CAGR +10.1%.
  • Net margin at 6.91% (contracting ▼).
  • Return on equity -129.24%, ROA 3.15%, ROIC 24.62%.
  • Gross margin 0.00%, operating margin 24.65%.
  • Free cash flow margin 29.13% ($17.82B).
  • Net income down ▼ +1.2% YoY.
  • Debt/equity -10.87, current ratio 0.81, net debt $57.93B.
  • Asset turnover 0.45 — capital efficiency.
Revenue (FY)
$61.16B
YoY +8.6%
Net margin
6.91%
▼ 13.48pp
ROE
-129.24%
ROA 3.15%
ROIC
24.62%
EPS (diluted)
$2.36
FY2025
Free cash flow
$17.82B
29.13% margin
Debt / equity
-10.87
Cash $6.57B
Current ratio
0.81
Equity -$5.93B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
FYRevenueRev YoYGross%Op%Net%FCFROE%
2024$56.33B+3.7%0.0016.227.59$17.83B128.66
2025$61.16B+8.6%0.0024.656.91$17.82B-129.24
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
Quarter endRevenueYoYQoQNet margin
Sep 30, 2024$14.46B+3.8%—10.80%
Mar 31, 2025$13.34B+8.4%-7.7%9.64%
Jun 30, 2025$15.42B+6.6%+15.6%6.08%
Sep 30, 2025$15.78B+9.1%+2.3%1.18%
Mar 31, 2026$15.00B+12.4%-4.9%4.63%
Jun 30, 2026$16.99B+10.2%+13.3%21.27%
Sources:SEC EDGAR — Company Facts (XBRL)
+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst
score -70Deteriorating
95% conf

Market cap $470.00B at $265.97 per share. Trailing P/E 112.70, P/S 7.68. EV/Operating income ≈ 35.02 (EV $527.93B).

  • Market cap $470.00B at $265.97 per share.
Market cap
$470.00B
1.77B shares
P/E (ttm)
112.70
P/S
7.68
P/B
—
EV
$527.93B
Intrinsic (DCF)
$183.47
-31.0% vs price
ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst
score 65Improving
85% conf

Price $265.97 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 59.34.

  • Price $265.97 — uptrend (above 200-DMA); 1-month momentum positive.
Price
$265.97
NYQ
RSI(14)
59.34
50-DMA
$246.46
200-DMA
$226.08
Volatility (ann.)
26.38%
52w range
$190.75–$267.47
-0.6% from high
ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst
score 30Improving
80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

  • Market regime: Risk-on · Supportive.
GDP growth
1.50%
CPI (YoY)
+3.3%
Fed funds
3.63%
10Y yield
4.71%
10Y−2Y
0.46pp
Unemployment
4.10%
ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst
score -24Deteriorating
83% conf

Composite risk Elevated. Leverage debt/equity -10.87 (low). Liquidity current ratio 0.81 (stretched).

  • Composite risk: Elevated.
Risk level
Elevated
Debt / equity
-10.87
Current ratio
0.81
Margin stdev
10.96pp
Cash / assets
4.86%
Liab / assets
—
ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to ProCreate free account

3 sections free · 4 Pro previews · composite -7

Macro exposure

Defensive · Low sensitivity
Neutral

Macro regime: Risk-on · Supportive. AbbVie Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
15.84
Fed funds
3.63%
CPI YoY
+3.3%

Analytical read

deterministic preview

Price $265.97 — uptrend (above 200-DMA); 1-month momentum positive..

Risk
Elevated
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Open analytical workspace

Peer comparison

Defensive group

How ABBV stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

CompanyScoreMacro
DexCom Inc. DXCM19Neutral
Bristol-Myers Squibb BMY19Neutral
Eli Lilly & Co. LLY17Neutral
HCA Healthcare HCA9Neutral
Gilead Sciences GILD8Neutral
Johnson & Johnson JNJ8Neutral
Abbott Laboratories ABT7Neutral
Biogen Inc. BIIB7Neutral
Intuitive Surgical Inc. ISRG7Neutral
Coca-Cola Co. KO6Neutral
Zoetis Inc. ZTS6Neutral
Thermo Fisher Scientific TMO3Neutral
Regeneron Pharmaceuticals REGN3Neutral
Danaher Corp. DHR1Neutral
Merck & Co. MRK0Neutral
Illumina Inc. ILMN0Neutral
Colgate-Palmolive CL-2Neutral
Vertex Pharmaceuticals VRTX-2Neutral
AbbVie Inc. ABBV● you-7Neutral
Procter & Gamble PG-7Neutral
CVS Health Corp. CVS-8Neutral
Walmart Inc. WMT-8Neutral
Mondelez International MDLZ-10Neutral
Amgen Inc. AMGN-10Neutral
Cigna Group CI-11Neutral
Kroger Co. KR-12Neutral
Costco Wholesale COST-14Neutral
Pfizer Inc. PFE-15Neutral
PepsiCo Inc. PEP-16Neutral
Sysco Corp. SYY-16Neutral
Hershey Co. HSY-17Neutral
Kimberly-Clark Corp. KMB-18Neutral
Moderna Inc. MRNA-21Neutral
UnitedHealth Group UNH-25Neutral